R&D for development of new drugs for neglected diseases in India

International Journal of Technology and Globalisation

Volumn 5, Issue 1-2, 2010, Pages 61-75

  Chaudhuri, Sudip ^a  

^a INDIAN INSTITUTE OF MANAGEMENT CALCUTTA   (India)

Author keywords

India; Neglected diseases; Pharmaceutical industry; TRIPS

Indexed keywords

EID: 77953924242     PISSN: 14765667     EISSN: 17418194     Source Type: Journal    
DOI: 10.1504/IJTG.2010.033666     Document Type: Article

References (27)

1. Baker, D. (2004) Financing Drug Research: What are the Issues?, Center for Economic and Policy Research, Issue Brief, Washington DC.
2. Center for Global Development Working Group (2004) Making Markets for Vaccines: A Practical Plan, Consultation Draft Report of the Working Group, Center for Global Development and Global Health Policy Research Network.
3. Chaudhuri, S. (2005) The WTO and India's Pharmaceuticals Industry: Patent Protection, TRIPS and Developing Countries, Oxford University Press, New Delhi.
4. CIPIH (2006) Public Health Innovation and Intellectual Property Rights, Report of the Commission on Intellectual property Rights, Innovation and Public Health, World Health Organization, Geneva.
5. Correa, C. (2001) Patent Law, TRIPS, and R&D Incentives: A Southern Perspective, WHO Commission on Macroeconomics and Health, CMH Working Paper Series, Paper No. WG2:12.
6. DBT (2009) Annual Report 2008-2009, Department of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi.
7. DND Working Group (2001) Fatal Imbalance: The Crisis in Research and Development for Drugs for Neglected Diseases, Medecins Sans Frontieres and Drugs for Neglected Diseases Working Group, Geneva.
8. DST (2009) Research and Development Statistics: 2007-2008, Department of Science and Technology, Government of India, New Delhi.
9. German, V. and Pascale, B. (1999) Globalization and Access to Drugs: Perspectives on the WTO/TRIPS Agreement, Health Economics and Drugs, DAP Series No. 7 (Revised), World Health Organization, Geneva.
10. IFPMA (2004) Research and Development for Neglected Diseases: Lessons Learnt and Remaining Challenges, International Federation of Pharmaceutical Manufacturers Associations, Geneva.
11. Kettler, H. E and Collins, C. (2002) Using Innovative Action to Meet Global Health Needs through Existing Intellectual Property Regimes, Study paper 2b, Commission on Intellectual property Rights, London.
12. Kettler, H. E., White, K. and Jordan, S. (2003) Valuing Industry Contributions to Public-Private Partnerships for Health Product Development, The Initiative on Public-Private Partnerships for Health, Geneva.
13. Lacetera, N. and Orsenigo, L. (2001) 'Political regimes, technological regimes and innovation in the evolution of the pharmaceutical industry in the USA and in Europe', Paper prepared for the Conference on Evolutionary Economics, Johns Hopkins University, Baltimore, 30-31 March.
14. Lanjouw, J. O. and Cockburn, I. M. (2001) 'New pills for poor people? - Empirical evidence after GATT', World Development, Vol. 29, No. 2, pp. 265-289.
15. Mani, S. (2002) Government Innovation and Technology Policy, Edward Elgar, Cheltenham.
16. Mashelkar Committee (1999) Report of the Pharmaceutical Research and Development Committee, Ministry of Chemicals and Fertilizers, Government of India, New Delhi.
17. Moran, M., Guzman, J., Henderson, K., Ropars, A-L., McDonald, A., McSherry, L., Wu, L., Omune, B., Illmer, A., Sturm, T. and. and Zmudzki, F. (2009) Neglected Disease R&D: New Times, New Trends, George Institute for International Health, Sydney and London.
18. Morris, J., Stevens, P. and van Gelder, A. (2005) Incentivising Research and Development for the Diseases of Poverty, International Policy Network, London (accessed from www.policynetwork.net).
19. NIHCM (2000) Prescription Drugs and Intellectual Property Protection, National Institute for Health Care Management Research and Educational Foundation, Issue Brief, August, Washington.
20. Nwaka, S. and Ridley, R. G. (2003) 'Virtual drug discovery and development for neglected diseases through public-private partnerships', Nature Reviews, Vol. 2, November, pp. 919-928.
21. Planning Commission (2006) Report of the Working Group on Drugs and Pharmaceuticals for the Eleventh Five Year Plan (2007-2011), Planning Commission, New Delhi.
22. Ray, A. S. (2003) A Study of R&D Incentives in India: Structural Changes and Impact, A project sponsored by the Department of Science and Technology, Government of India.
23. Scherer, F. M and Weisburst, S. (1995) 'Economic effects of strengthening pharmaceutical patent protection in Italy', International Review of Industrial and Copyright Law, Vol. 26, pp. 1009-1024.
24. Singh, M. M. (2006) 'Will India become the global centre for pharmaceutical research & development', Journal of Generic Medicines, Vol. 3, No. 3, pp. 194-200.
25. Torreele, E., Usdin, M. and Chirac, P. (2004) 'A needs-based pharmaceutical R&D agenda for neglected diseases', Background paper prepared for the Priority Medicines for Europe and the World Project, A Public Health Approach to Innovation.
26. Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R. and Ford, N. (2002) 'Drug development for neglected diseases: a deficient market and a public health policy failure', The Lancet, 23 June, Vol. 359, pp. 2188-2194.
27. WHO (2004) The World Medicines Situation, World Health Organization, Geneva.